SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors -November 04, 2023 at 12:52 pm EDT
Phase 1 Trial of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced With Genetic and Epigenetic Reprogramming, in Advanced Triple-Negative...
Source: marketscreener.com